This led to the approval of trastuzumab as the first molecular targeted therapy for GC, however not all patients with HER2-positive GC respond to trastuzumab, and the majority of patients who respond develop resistance after a relatively short period of time [15]. Here, ERBB2 is linked to gastric cancer.